An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton ’s Tyrosine Kinase Inhibitor

ConclusionsCC-292 was well tolerated when administered to healthy subjects as single oral doses under all conditions. Food intake had no clinically relevant impact on CC-292 pharmacokinetics compared to fasted conditions. Therefore, CC-292 can be administered with or without food. Co-administration of CC-292 with multiple doses of omeprazole (40 mg) decreased the pharmacokinetic exposure of CC-292. However, the effect was not clinically relevant.Clinical Trials RegistrationNCT02433457

http://rd.springer.com/10.1007/s13318-022-00776-7

Source: European Journal of Drug Metabolism and Pharmacokinetics - June 3, 2022 Category: Drugs & Pharmacology Source Type: research